Preservatives News and Research

RSS

Rock Sake traditional white spirits are gluten and sulfite free

The movement toward high quality, all natural food and drink continues to gain momentum and Americans need a cocktail that fits in with their healthy lifestyle. Rock Sake is a line of ultra-premium, domestically produced sake that is a delicious and nutritious alternative to traditional white spirits. Per ounce, Rock Sake is half the calories of vodka, rum and other white spirits and is gluten and sulfite free.

25 Aug 2010

Smart for Life continues to improve Chocolate Chip Cookie

The trailblazing company whose Smart for Life weight management products featuring the cookie diet component has recently improved its Chocolate Chip Cookie to include the most protein offered in a meal replacement cookie on the market at a whopping 6 grams per serving. The amount of protein found in meal replacements is instrumental in curbing hunger, maintaining muscle mass, and providing energy, not to mention contributing to weight loss.

16 Aug 2010

Sodium Working Group recommends reducing sodium intake among Canadians

The federally-mandated Sodium Working Group has released the Sodium Reduction Strategy for Canada. The three-pronged strategy contains six over-arching and 27 specific recommendations for a population health strategy for reducing sodium intake among Canadians.

31 Jul 2010

Alcon second-quarter global sales increase 12.5% to $1.89 billion

Alcon, Inc. reported that global sales rose 12.5 percent to $1.89 billion for the second quarter of 2010, or 11.3 percent excluding the impact of foreign exchange fluctuations and acquisitions. Revenue from acquisitions added 40 basis points to sales growth in the quarter, while foreign currency fluctuations added 80 basis points of growth.

27 Jul 2010

Study reveals improved process to obtain, store RNA from lung tumor biopsies

Analyzing the genes expressed by cancer cells allows for a better understanding of that patient's specific disease and in turn, a more personalized approach to treatment. But obtaining the RNA from a tumor in the lungs in order to conduct the genetic analysis is a challenging prospect. Currently, lung cancer researchers are limited to using RNA extracted from early-stage tumors removed during surgery. The small quantities of tissue extracted during routine diagnostic biopsies have not been useful to researchers, due to their small size and the variety of ways they have been processed.

16 Jul 2010

APP receives FDA marketing clearance for preservative-free Heparin Lock Flush Solution

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market preservative-free Heparin Lock Flush Solution, USP in two dosage strengths, 10 USP Units/1 mL and 100 USP Units/1 mL, and will soon launch these single dose vial presentations.

6 Jul 2010

OTA reminds consumers to choose organic foods over synthetic dye foods

In response to a call from the Center for Science in the Public Interest (CSPI) to ban synthetic dyes to color foods, the Organic Trade Association (OTA) today reminded consumers that they can already avoid such dyes in the marketplace by choosing to purchase organic foods.

2 Jul 2010

Increasing the amount of preservatives may reduce food poisoning

In response to consumer demand for more natural food, the food industry has reduced the amount of preservatives in food over recent years. A common preservative is acetic acid, which is used to stop bacterial growth in dressings, sauces, cheese and pickles.

25 Jun 2010

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.

11 Jun 2010

PURE Bioscience's anhydrous SDC technology granted US patent

PURE Bioscience today announced that the United States Patent and Trademark Office issued patent number 7,732,486, which covers PURE's anhydrous silver dihydrogen citrate technology.

10 Jun 2010

PuriCore sales decreases 9.9% to $10.0 million for first-quarter 2010

PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today issued its Interim Management Statement covering the period January 1, 2010, to March 31, 2010.

28 May 2010

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Allergan, Inc. today announced that the United States Food and Drug Administration has approved ZYMAXID (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms; Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumonia.

20 May 2010

FDA approves Sagent's bacitracin for pneumonia and empyema

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced FDA approval of bacitracin for injection, USP (bacitracin), an anti-infective product used to treat pneumonia and empyema. Bacitracin will be offered in a 50,000 MU, AP-rated, preservative-free, latex-free, single-dose vial packaged both individually and in packages of ten.

13 May 2010

Oncology unit of Jewish General Hospital focuses on Smart for Life cookies

Smart for Life cookies will be the focus of a study in the oncology unit of the Jewish General Hospital, acknowledged as a world leader in many fields of investigation and a key teaching site for McGill University.

29 Apr 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

Cancer Prevention Coalition's statement on new nominated NCI Director

Last Wednesday, the White House nominated Nobel Laureate Harold Varmus as Director of the National Cancer Institute.

3 Apr 2010

Natural Vines introduced for sophisticated licorice customers

American Licorice Company, one of the nation's most respected licorice manufacturers, has introduced Natural Vines, a new line of premium, gourmet soft licorice created for the discerning licorice connoisseur.

31 Mar 2010

Bistro MD offers doctor-designed, chef-prepared gourmet meals

In recent years, the options for weight loss products and services have greatly expanded. The National Center for Health Statistics reported that more than 34% of Americans are currently considered obese. As a result of these dramatic statistics, more people are turning towards creative solutions to help them to achieve their weight loss goals.

27 Mar 2010

Washington State mercury-limit suspension for swine flu vaccine ends

When it comes to some diseases prevention still is better than cure and swine flu is one such disease. The sheer global panic that gripped nations last year is hard to forget. The PanvaxH1N1 vaccine is specifically manufactured to target the influenza (A) H1N1 strain known more popularly as swine flu. Getting the flu shots may be crucial in prevention of spread of the highly contagious disease. Health officials say that the H1N1 strain of flu is still circulating but at low levels.

24 Mar 2010

FDA approves APP Pharmaceuticals' Indomethacin for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.

23 Mar 2010